CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 381 enrolled / 381 target
Drug / intervention
Secukinumab 300 mg +2 moredrug
Likely dose
Secukinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05767034
NCT05767034Phase 3CompletedMonitor (9.7/mo)Completion was 9mo ago
CompareCT.gov

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Novartis Pharmaceuticals·interventional·Posted Mar 14, 2023·Updated Jun 22, 2026

In Brief

A Phase 3 clinical trial evaluating Secukinumab 300 mg, Secukinumab 150 mg, and 1 other intervention for Polymyalgia Rheumatica. Completed, enrolled 381 participants across 132 sites in 26 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolymyalgia Rheumatica
CountriesArgentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Lebanon, Mexico, Netherlands, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMar 14, 2023
Enrollment StartMar 22, 2023
Primary CompletionSep 10, 2025
Study CompletionFeb 16, 2026
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 3.3 years ago

Arms & Interventions

Secukinumab 300 mgexperimental

randomized in 1:1:1 ratio every 4 weeks

Drug: Secukinumab 300 mg
Secukinumab 150 mgexperimental

randomized in 1:1:1 ratio every 4 weeks

Drug: Secukinumab 150 mg
Placebo to secukinumabplacebo_comparator

randomized in 1:1:1 ratio every 4 weeks

Other: Placebo to secukinumab

Interventions

Secukinumab 300 mgdrug

Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen

Secukinumab 150 mgdrug

Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen

Placebo to secukinumabother

Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen